|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123173 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-22 11:33:59 |
|
注册时间: Date of Registration: |
2026-04-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
rTMS增强运动想象脑机接口改善脑卒中后上肢功能障碍的应用研究 |
|
Public title: |
Application research on rTMS-enhanced motor imagery brain-computer interface for improving upper limb dysfunction after stroke |
|
注册题目简写: |
|
|
English Acronym: |
Research on enhancing the therapeutic effects of clinical applications of brain-computer interfaces |
|
研究课题的正式科学名称: |
rTMS增强运动想象脑机接口改善脑卒中后上肢功能障碍的应用研究 |
|
Scientific title: |
Application research on rTMS-enhanced motor imagery brain-computer interface for improving upper limb dysfunction after stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
靳令经 |
研究负责人: |
靳令经 |
|
Applicant: |
Lingjing Jin |
Study leader: |
Lingjing Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 21 66111329 |
研究负责人电话:
Study leader's |
+86 21 66111329 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lingjingjin@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lingjingjin@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市松江区光星路2209号 |
研究负责人通讯地址: |
上海市光星路2209号 |
|
Applicant address: |
2209 Guangxing Road, Songjiang District, Shanghai |
Study leader's address: |
2209 Guangxing Road, Songjiang District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市养志康复医院(上海阳光康复中心) |
||
|
Applicant's institution: |
Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Hospital) |
||
|
研究负责人所在单位: |
上海市养志康复医院 |
||
|
Affiliation of the Leader: |
Shanghai Yangzhi rehabilitation hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
养志伦审字〔2026〕010号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市养志康复医院(上海市阳光康复中心)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Yangzhi Rehabilitation Hospital Shanghai Sunshine Rehabilitation Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-28 00:00:00 | ||
|
伦理委员会联系人: |
王涛 |
||
|
Contact Name of the ethic committee: |
Wang Tao |
||
|
伦理委员会联系地址: |
上海市光星路2209号 |
||
|
Contact Address of the ethic committee: |
2209 Guangxing Road, Songjiang District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 37730011 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
13644870352@163.com |
|
研究实施负责(组长)单位: |
上海市养志康复医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Yangzhi rehabilitation hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市光星路2209号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2209 Guangxing Road, Songjiang District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海申康医院发展中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Hospital Development Center |
||||||||||||||||||||||
|
研究疾病: |
脑卒中后上肢运动功能障碍 |
||||||||||||||||||||||
|
Target disease: |
Upper limb motor dysfunction after stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证MI-BCI康复干预的临床疗效,识别“BCI盲”典型特征并建立风险评估体系,探索rTMS干预对“BCI盲”患者的增效作用, |
||||||||||||||||||||||
|
Objectives of Study: |
To verify the clinical efficacy of the MI-BCI rehabilitation intervention, identify the typical characteristics of "BCI blindness" and establish a risk assessment system, and explore the enhancing effect of rTMS on patients with "BCI illiteracy". |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
第一部分: 1.经头颅CT或MRI确诊为脑卒中(包括缺血性卒中或出血性卒中),且卒中后遗留单侧上肢运动功能障碍(改良Fugl-Meyer上肢评分FMA-UE≤60分); 2.年龄18~75 岁; 3.病程>=2周; 4.患侧上肢肌张力未达痉挛期(改良Ashworth分级<=2级); 5.简易精神状态检查(MMSE)评分>=24分,患者需具备理解运动想象任务(如想象抓握、伸展)及配合 2 周康复训练的能力。 第三部分 1.经头颅 CT 或 MRI 确诊为脑卒中(包括缺血性卒中或出血性卒中),且卒中后遗留单侧上肢运动功能障碍(改良 Fugl-Meyer 上肢评分 FMA-UE≤60 分); 2.年龄18~75 岁; 3.病程>=2周; 4.患侧上肢肌张力未达痉挛期(改良Ashworth分级<=2级); 5.符合“BCI 盲”高风险的诊断; 6.简易精神状态检查(MMSE)评分>=24分,患者需具备理解运动想象任务(如想象抓握、伸展)及配合康复训练的能力; 7.承诺完成 3 个月的随访(含功能评分、神经影像检查),并能定期至合作单位复诊. |
||||||||||||||||||||||
|
Inclusion criteria |
Part I: 1.Confirmed by head CT or MRI as a stroke (including ischemic stroke or hemorrhagic stroke), and with unilateral upper limb motor dysfunction remaining after the stroke (modified Fugl-Meyer Upper Extremity score FMA-UE <= 60 points); 2.Age 18 to 75 years old, both men and women; 3.Disease duration >= 2 weeks; 4.The muscle tone of the affected upper limb has not reached the spastic stage (modified Ashworth scale <= 2 grade); 5. Mini-Mental State Examination (MMSE) score >= 24, and the patient must have the ability to understand motor imagery tasks (e.g., imagining grasping and extending) and cooperate with a 2-week rehabilitation training. Part III: 1.Confirmed by head CT or MRI as a stroke (including ischemic stroke or hemorrhagic stroke), and with unilateral upper limb motor dysfunction remaining after the stroke (modified Fugl-Meyer Upper Extremity score FMA-UE <= 60 points); 2.Age 18 to 75 years old, both men and women; 3.Disease duration >= 2 weeks; 4.The muscle tone of the affected upper limb has not reached the spastic stage (modified Ashworth scale <= 2 grade); 5.Meeting the diagnostic criteria for high risk of "BCI blindness"; 6.Mini-Mental State Examination (MMSE) score >= 24, and the patient must have the ability to understand motor imagery tasks (e.g., imagining grasping and extending) and cooperate with rehabilitation training; 7.Commitment to complete 3 months of follow-up (including functional assessment and neuroimaging examination), and ability to regularly attend follow-up visits at the collaborating institution. |
||||||||||||||||||||||
|
排除标准: |
1.继发性瘫痪:因外伤、神经退行性疾病(如帕金森病、肌萎缩侧索硬化症)、先天性神经肌肉疾病(如脊髓性肌萎缩症)导致的上肢运动障碍; 2.合并严重系统性疾病:合并严重心脑血管疾病(如未控制的高血压、冠心病、癫痫)、精神疾病(如抑郁症、精神分裂症); 3.既往BCI相关干预:初次参与本研究前已接受过基于运动想象的脑机接口康复训练; 4.皮肤或体表禁忌症:患侧上肢皮肤存在破损、炎症或金属植入物(如骨折内固定),影响EEG电极贴附或TMS刺激安全性; 5.癫痫风险:既往有癫痫发作史或卒中后新发癫痫,且未规律抗癫痫药物治疗; 6.药物干扰:正在服用抗癫痫药物(如苯二氮?类)、镇静剂(如苯二氮?类、巴比妥酸盐)。 第三部分: 1.继发性瘫痪:因外伤、神经退行性疾病(如帕金森病、肌萎缩侧索硬化症)、先天性神经肌肉疾病(如脊髓性肌萎缩症)导致的上肢运动障碍; 2.合并严重系统性疾病:合并严重心脑血管疾病(如未控制的高血压、冠心病、癫痫)、精神疾病(如抑郁症、精神分裂症); 3.既往BCI相关干预:初次参与本研究前已接受过基于运动想象的脑机接口康复训练; 4.皮肤或体表禁忌症:患侧上肢皮肤存在破损、炎症或金属植入物(如骨折内固定),影响EEG电极贴附或TMS刺激安全性; 5.癫痫风险:既往有癫痫发作史或卒中后新发癫痫,且未规律抗癫痫药物治疗; 6.药物干扰:正在服用抗癫痫药物(如苯二氮?类)、镇静剂(如苯二氮?类、巴比妥酸盐); |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Secondary paralysis: Motor dysfunction of the upper limbs caused by trauma, neurodegenerative diseases (such as Parkinson's disease, amyotrophic lateral sclerosis), or congenital neuromuscular disorders (such as spinal muscular atrophy); 2.Comorbid severe systemic diseases: Comorbid with severe cardiovascular and cerebrovascular diseases (such as uncontrolled hypertension, coronary heart disease, epilepsy), mental disorders (such as depression, schizophrenia); 3.Previous BCI-related interventions: Before participating in this study for the first time, they had already received rehabilitation training based on motor imagery using brain-computer interfaces. 4.Skin or body surface contraindications: If the skin on the affected upper limb is damaged, inflamed, or has metal implants (such as internal fixation for fractures), it may interfere with the attachment of EEG electrodes or the safety of TMS stimulation; 5.Epilepsy risk: History of previous epileptic seizures or new-onset epilepsy after stroke, and no regular antiepileptic drug treatment; 6.Drug interference: Currently taking antiepileptic drugs (such as benzodiazepines), sedatives (such as benzodiazepines, barbiturates). Part III: 1.Secondary paralysis: Motor dysfunction of the upper limbs caused by trauma, neurodegenerative diseases (such as Parkinson's disease, amyotrophic lateral sclerosis), or congenital neuromuscular disorders (such as spinal muscular atrophy); 2.Comorbid severe systemic diseases: Comorbid with severe cardiovascular and cerebrovascular diseases (such as uncontrolled hypertension, coronary heart disease, epilepsy), mental disorders (such as depression, schizophrenia); 3.Previous BCI-related interventions: Before participating in this study for the first time, they had already received rehabilitation training based on motor imagery using brain-computer interfaces. 4.Skin or body surface contraindications: If the skin on the affected upper limb is damaged, inflamed, or has metal implants (such as internal fixation for fractures), it may interfere with the attachment of EEG electrodes or the safety of TMS stimulation; 5.Epilepsy risk: History of previous epileptic seizures or new-onset epilepsy after stroke, and no regular antiepileptic drug treatment; 6.Drug interference: Currently taking antiepileptic drugs (such as benzodiazepines), sedatives (such as benzodiazepines, barbiturates); 7.Contraindications for TMS: presence of intracranial metal implants, such as cardiac pacemakers or intracranial electrodes; 8.Currently receiving other neuromodulation techniques, such as tDCS, |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-01 00:00:00至 To 2029-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2029-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Table of random numbers |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对研究参与者、评估者设盲 |
|
Blinding: |
Blinding study participants and evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |